The medications most likely to cause thyroid eye disease are alemtuzumab, certain immune checkpoint inhibitors, amiodarone ...

Emerging growth opportunities in the next-generation immune checkpoint inhibitors market include the development of therapies targeting novel immune pathways employed to tackle cancer resistance ...

Immunotherapies such as so-called checkpoint inhibitors activate the body's own immune system to fight cancer cells and have ...

Phase 2 study to evaluate combination therapy in patients with metastatic colorectal cancer, targeting β-catenin-driven immune exclusion in liver ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...

For the past 15 years or so, a class of drugs called immune checkpoint inhibitors have been used to treat melanoma – the most ...

Adverse events profile of novel agents targeting immune checkpoints beyond PD-1/PD-L1 and CTLA-4 in solid tumors: A meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated ...

MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...

When immune checkpoint inhibitors are used in cancer treatment, in some cases it can lead to severe inflammation and damage to heart tissue. Histology images of mouse heart tissue illustrate the ...